glp 1 agonist and dementia Potential Role of Glucagon-like Peptide-1 Receptor Agonists in the Treatment of Cognitive Decline in Diabetes Mellitus GLP-1s and Reduced Risk of
Description
N Engl J Med 373(23):22472257 Muskiet MHA, Tonneijck L, Huang Y, Liu M, Saremi A, Heerspink HJL et al (2018) Lixisenatide and renal outcomes in patients with type 2 diabetes and acute coronary syndrome: an exploratory analysis of the ELIXA randomised, placebo-controlled trial

doi: 10.1038/s41574-018-0016-2 20 CampbellJEDruckerDJ

B., Das, S

Long term loss of muscle mass has been associated with osteoporosis and other health issues

Dulaglutide is only given at the one dose of 1.5 mg once weekly at any time of day, independent of meals

Diabetes 10 (5), 291303